Erken ve Lokal İleri Kolon Kanseri
Özet
Kolorektal kanserler (KRK) kanserler arasında en sık görülen olup günümüzde tarama programları ile daha erken evrelerde tanı konmaktadır. Bu nedenle de cerrahi ile küratif yaklaşımlar bu hasta grubunda daha sık uyuglanır. Cerrahi sonrası bazı hastaların adjuvan kemoterapiye ihtiyacı olur. Tedaviler tamamlandıktan sonra hastalar belirli aralıklarla bazı testlerin uygulandığı takip programına alınır. Hastalığın nüks etme riski ilk 3 yılda daha yüksek olup 5. yıldan sonra bu risk azalır. İlk 3 yıl 3-6 ayda bir fizik muayene yapılması, CEA düzeyine bakılması, evre II-III hasta grubu içinse yıllık toraks ve batının değerlendirildiği bilgisayarlı tomografi çekimi önerilir. Sonraki iki yılda ise bu testler 6-12 ayda bir, 5 yılın sonunda ise yılda bir yapılır. İntraluminal patolojilerin değerlendirilmesi açısından postoperatif 1. yılda kontrol kolonoskopi yapılır. Bu takip önerileri ülkelere, merkezlere göre değişebilmektedir.
Colorectal cancers (CRC) are among the most common cancers, and with today's screening programs, they are diagnosed at earlier stages. Therefore, curative surgical approaches are more frequently applied to this patient group. After surgery, some patients may require adjuvant chemotherapy. Once treatments are completed, patients are included in a follow-up program where certain tests are performed at regular intervals. The risk of disease recurrence is higher in the first three years and decreases after the fifth year. It is recommended to perform a physical examination every 3–6 months and measure CEA levels during the first three years. For stage II–III patients, an annual computed tomography (CT) scan of the thorax and abdomen is advised. In the following two years, these tests are conducted every 6–12 months, and after five years, they are done annually. To evaluate intraluminal pathologies, a follow-up colonoscopy is performed in the first postoperative year. These follow-up recommendations may vary between countries and medical centers.
Referanslar
Adam M, Chang GJ, Chen YJ, Ciombor KK, Cohen SA, Deming D, et al. NCCN Guidelines Version 1.2025 Colon Cancer Continue NCCN Guidelines Panel Disclosures. 2025 [cited 2025 Mar 30]; Available from: https://www.nccn.org/home/member-
Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2020 Oct 1 [cited 2025 Mar 30];31(10):1291–305. Available from: https://pubmed.ncbi.nlm.nih.gov/32702383/
Castells A, Bessa X, Daniels M, Ascaso C, Lacy AM, García-Valdecasas JC, et al. Value of postoperative surveillance after radical surgery for colorectal cancer: results of a cohort study. Dis Colon Rectum [Internet]. 1998 [cited 2025 Mar 30];41(6):714–23. Available from: https://pubmed.ncbi.nlm.nih.gov/9645739/
Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg [Internet]. 1998 Jul [cited 2025 Mar 30];228(1):59–63. Available from: https://pubmed.ncbi.nlm.nih.gov/9671067/
Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, et al. Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. Journal of Clinical Oncology [Internet]. 2013 Dec 10 [cited 2025 Mar 30];31(35):4465–70. Available from: https://ascopubs.org/doi/10.1200/JCO.2013.50.7442
Martin EW, Cooperman M, Carey LC, Minton JP. Sixty second-look procedures indicated primarily by rise in serial carcinoembryonic antigen. J Surg Res [Internet]. 1980 [cited 2025 Mar 30];28(5):389–94. Available from: https://pubmed.ncbi.nlm.nih.gov/7392594/
Hine KR, Dykes PW. Serum CEA testing in the post-operative surveillance of colorectal carcinoma. Br J Cancer [Internet]. 1984 [cited 2025 Mar 30];49(6):689–93. Available from: https://pubmed.ncbi.nlm.nih.gov/6733018/
McCall JL, Black RB, Rich CA, Harvey JR, Baker RA, Watts JM, et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum [Internet]. 1994 Sep [cited 2025 Mar 30];37(9):875–81. Available from: https://pubmed.ncbi.nlm.nih.gov/8076486/
Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study - PubMed [Internet]. [cited 2025 Mar 30]. Available from: https://pubmed.ncbi.nlm.nih.gov/3971297/
Chau I, Allen MJ, Cunningham D, Norman AR, Brown G, Ford HER, et al. The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer. Journal of Clinical Oncology [Internet]. 2004 [cited 2025 Mar 31];22(8):1420–9. Available from: https://ascopubs.org/doi/10.1200/JCO.2004.05.041
Passman MA, Pommier RF, Vetto JT. Synchronous colon primaries have the same prognosis as solitary colon cancers. Dis Colon Rectum [Internet]. 1996 Mar [cited 2025 Mar 31];39(3):329–34. Available from: https://pubmed.ncbi.nlm.nih.gov/8603557/
Ringland CL, Arkenau HT, O’Connell DL, Ward RL. Second primary colorectal cancers (SPCRCs): experiences from a large Australian Cancer Registry. Ann Oncol [Internet]. 2010 Jul 21 [cited 2025 Mar 31];21(1):92–7. Available from: https://pubmed.ncbi.nlm.nih.gov/19622595/
Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016 Mar 1;150(3):758-768.e11.
Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med [Internet]. 2013 Sep 19 [cited 2025 Mar 31];369(12):1095–105. Available from: https://pubmed.ncbi.nlm.nih.gov/24047059/
Tsikitis VL, Malireddy K, Green EA, Christensen B, Whelan R, Hyder J, et al. Postoperative Surveillance Recommendations for Early Stage Colon Cancer Based on Results From the Clinical Outcomes of Surgical Therapy Trial. J Clin Oncol [Internet]. 2009 [cited 2025 Mar 30];27:3671–6. Available from: www.jco.org
Hardiman KM, Felder SI, Friedman G, Migaly J, Paquette IM, Feingold DL. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surveillance and Survivorship Care of Patients after Curative Treatment of Colon and Rectal Cancer. Dis Colon Rectum [Internet]. 2021 May 1 [cited 2025 Mar 30];64(5):517–33. Available from: https://journals.lww.com/dcrjournal/fulltext/2021/05000/the_american_society_of_colon_and_rectal_surgeons.6.aspx
Jeerym JM, Hickeybe H. Cochrane Library Cochrane Database of Systematic Reviews Follow-up strategies for patients treated for non-metastatic colorectal cancer (Review) Follow-up strategies for patients treated for non-metastatic colorectal cancer (Review). 2019 [cited 2025 Mar 30]; Available from: www.cochranelibrary.com
Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, et al. Effect of 3 to 5 Years of Scheduled CEA and CT Follow-up to Detect Recurrence of Colorectal Cancer: The FACS Randomized Clinical Trial. JAMA [Internet]. 2014 Jan 15 [cited 2025 Mar 30];311(3):263–70. Available from: https://jamanetwork.com/journals/jama/fullarticle/1814213
Wille-Jørgensen P, Syk I, Smedh K, Laurberg S, Nielsen DT, Petersen SH, et al. Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer–Specific Mortality in Patients With Stage II or III Colorectal Cancer: The COLOFOL Randomized Clinical Trial. JAMA [Internet]. 2018 May 22 [cited 2025 Mar 30];319(20):2095–103. Available from: https://jamanetwork.com/journals/jama/fullarticle/2681744
Snyder R, Hu CY, Cuddy A, Francescatti AB, Schumacher JR, Loon K Van, et al. Association Between Intensity of Post-Treatment Surveillance Testing, Detection of Recurrence, and Survival in Patients with Stage I-III Colorectal Cancer (AFT-02) HHS Public Access. JAMA. 2018;319:2104–15.
